Literature DB >> 26668743

Submucosal invasion and risk of lymph node invasion in early Barrett's cancer: potential impact of different classification systems on patient management.

Dimitrios Fotis1, Michael Doukas2, Bas Pl Wijnhoven3, Paul Didden1, Katharina Biermann2, Marco J Bruno1, Arjun D Koch1.   

Abstract

BACKGROUND: Due to the high mortality and morbidity rates of esophagectomy, endoscopic mucosal resection (EMR) is increasingly used for the curative treatment of early low risk Barrett's adenocarcinoma.
OBJECTIVE: This retrospective cohort study aimed to assess the prevalence of lymph node metastases (LNM) in submucosal (T1b) esophageal adenocarcinomas (EAC) in relation to the absolute depth of submucosal tumor invasion and demonstrate the efficacy of EMR for low risk (well and moderately differentiated without lymphovascular invasion) EAC with sm1 invasion (submucosal invasion ≤500 µm) according to the Paris classification.
METHODS: The pathology reports of patients undergoing endoscopic resection and surgery from January 1994 until December 2013 at one center were reviewed and 54 patients with submucosal invasion were included. LNM were evaluated in surgical specimens and by follow up examinations in case of EMR.
RESULTS: No LNM were observed in 10 patients with sm1 adenocarcinomas that underwent endoscopic resection. Three of them underwent supplementary endoscopic eradication therapy with a median follow up of 27 months for patients with sm1 tumors. In the surgical series two patients (29%) with sm1 invasion according to the pragmatic classification (subdivision of the submucosa into three equal thirds), staged as sm2-3 in the Paris classification, had LNM. The rate of LNM for surgical patients with low risk sm1 tumors was 10% according to the pragmatic classification and 0% according to Paris classification.
CONCLUSION: Different classifications of the tumor invasion depth lead to different LNM risks and treatment strategies for sm1 adenocarcinomas. Patients with low risk sm1 adenocarcinomas appear to be suitable candidates for EMR.

Entities:  

Keywords:  Early Barrett’s cancer; Paris classification; endoscopic mucosal resection; lymph node metastases; sm1 esophageal adenocarcinoma; submucosal invasion

Year:  2015        PMID: 26668743      PMCID: PMC4669513          DOI: 10.1177/2050640615581965

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  24 in total

Review 1.  The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002.

Authors: 
Journal:  Gastrointest Endosc       Date:  2003-12       Impact factor: 9.427

2.  Risk stratification for early esophageal adenocarcinoma: analysis of lymphatic spread and prognostic factors.

Authors:  Andrew P Barbour; Mark Jones; Ian Brown; David C Gotley; Ian Martin; Janine Thomas; Andrew Clouston; B Mark Smithers
Journal:  Ann Surg Oncol       Date:  2010-03-27       Impact factor: 5.344

3.  Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction.

Authors:  Marinke Westerterp; Linetta B Koppert; Christianne J Buskens; Hugo W Tilanus; Fiebo J W ten Kate; Jacques J H G M Bergman; Peter D Siersema; Herman van Dekken; Jan J B van Lanschot
Journal:  Virchows Arch       Date:  2005-04-19       Impact factor: 4.064

4.  Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients.

Authors:  Giuseppe Portale; Jeffrey A Hagen; Jeffrey H Peters; Linda S Chan; Steven R DeMeester; Tasha A K Gandamihardja; Tom R DeMeester
Journal:  J Am Coll Surg       Date:  2006-04       Impact factor: 6.113

5.  The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens.

Authors:  Jessica M Leers; Steven R DeMeester; Arzu Oezcelik; Nancy Klipfel; Shahin Ayazi; Emmanuele Abate; Jörg Zehetner; John C Lipham; Linda Chan; Jeffrey A Hagen; Tom R DeMeester
Journal:  Ann Surg       Date:  2011-02       Impact factor: 12.969

6.  Esophageal cancer resection in the elderly.

Authors:  P Thomas; C Doddoli; P Neville; J Pons; P Lienne; R Giudicelli; M Giovannini; J F Seitz; P Fuentes
Journal:  Eur J Cardiothorac Surg       Date:  1996       Impact factor: 4.191

7.  Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features.

Authors:  Christianne J Buskens; Marinke Westerterp; Sjoerd M Lagarde; Jacques J G H M Bergman; Fiebo J W ten Kate; J Jan B van Lanschot
Journal:  Gastrointest Endosc       Date:  2004-11       Impact factor: 9.427

8.  Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma.

Authors:  Rami J Badreddine; Ganapathy A Prasad; Jason T Lewis; Lori S Lutzke; Lynn S Borkenhagen; Kelly T Dunagan; Kenneth K Wang
Journal:  Clin Gastroenterol Hepatol       Date:  2009-11-27       Impact factor: 11.382

9.  Early Barrett's carcinoma with "low-risk" submucosal invasion: long-term results of endoscopic resection with a curative intent.

Authors:  Hendrik Manner; Andrea May; Oliver Pech; Liebwin Gossner; Thomas Rabenstein; Erwin Günter; Michael Vieth; Manfred Stolte; Christian Ell
Journal:  Am J Gastroenterol       Date:  2008-09-10       Impact factor: 10.864

10.  Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion.

Authors:  Hendrik Manner; Oliver Pech; Yvonne Heldmann; Andrea May; Juergen Pohl; Angelika Behrens; Liebwin Gossner; Manfred Stolte; Michael Vieth; Christian Ell
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-26       Impact factor: 11.382

View more
  6 in total

1.  Measurement of the tumor invasion depth into the submucosa in early adenocarcinoma of the esophagus (pT1b): Can microns be the new standard for the endoscopist?

Authors:  Hendrik Manner; Oliver Pech
Journal:  United European Gastroenterol J       Date:  2015-12       Impact factor: 4.623

2.  Management of patients with T1b esophageal adenocarcinoma: a retrospective cohort study on patient management and risk of metastatic disease.

Authors:  Dirk Schölvinck; Hannah Künzli; Sybren Meijer; Kees Seldenrijk; Mark van Berge Henegouwen; Jacques Bergman; Bas Weusten
Journal:  Surg Endosc       Date:  2016-06-29       Impact factor: 4.584

3.  Risk of lymph node metastases in patients with T1b oesophageal adenocarcinoma: A retrospective single centre experience.

Authors:  David Graham; Nejc Sever; Cormac Magee; William Waddingham; Matthew Banks; Rami Sweis; Hannah Al-Yousuf; Miriam Mitchison; Durayd Alzoubaidi; Manuel Rodriguez-Justo; Laurence Lovat; Marco Novelli; Marnix Jansen; Rehan Haidry
Journal:  World J Gastroenterol       Date:  2018-11-07       Impact factor: 5.742

4.  Do pathologists agree with each other on the histological assessment of pT1b oesophageal adenocarcinoma?

Authors:  Annieke W Gotink; Fiebo Jc Ten Kate; Michael Doukas; Bas Pl Wijnhoven; Marco J Bruno; Leendert Hj Looijenga; Arjun D Koch; Katharina Biermann
Journal:  United European Gastroenterol J       Date:  2018-12-06       Impact factor: 4.623

5.  Endoscopic resection of Barrett's adenocarcinoma: Intramucosal and low-risk tumours are not associated with lymph node metastases.

Authors:  Nicolas Benech; Jean Marc O'Brien; Maximilien Barret; Jéremie Jacques; Gabriel Rahmi; Guillaume Perrod; Valérie Hervieu; Alexandre Jaouen; Aurélie Charissoux; Olivier Guillaud; Romain Legros; Thomas Walter; Jean-Christophe Saurin; Jérôme Rivory; Fréderic Prat; Vincent Lépilliez; Thierry Ponchon; Mathieu Pioche
Journal:  United European Gastroenterol J       Date:  2021-03-15       Impact factor: 4.623

6.  Endoscopic management and follow-up of patients with a submucosal esophageal adenocarcinoma.

Authors:  H T Künzli; K Belghazi; R E Pouw; S L Meijer; C A Seldenrijk; Blam Weusten; Jjghm Bergman
Journal:  United European Gastroenterol J       Date:  2018-01-29       Impact factor: 4.623

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.